AR085724A1 - ANALOGO DE LA SANGLIFERINA CON ACTIVIDAD INHIBIDORA DE mPTP - Google Patents
ANALOGO DE LA SANGLIFERINA CON ACTIVIDAD INHIBIDORA DE mPTPInfo
- Publication number
- AR085724A1 AR085724A1 ARP120101043A ARP120101043A AR085724A1 AR 085724 A1 AR085724 A1 AR 085724A1 AR P120101043 A ARP120101043 A AR P120101043A AR P120101043 A ARP120101043 A AR P120101043A AR 085724 A1 AR085724 A1 AR 085724A1
- Authority
- AR
- Argentina
- Prior art keywords
- sangliferina
- mptp
- analog
- inhibiting activity
- compound
- Prior art date
Links
- 108010067028 Mitochondrial Permeability Transition Pore Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229930194542 Keto Natural products 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1105293.3A GB201105293D0 (en) | 2011-03-29 | 2011-03-29 | Novel compounds and methods for their production |
| GBGB1113629.8A GB201113629D0 (en) | 2011-08-08 | 2011-08-08 | Novel compounds and methods for their production |
| GBGB1202060.8A GB201202060D0 (en) | 2012-02-07 | 2012-02-07 | Novel compounds and methods for their production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085724A1 true AR085724A1 (es) | 2013-10-23 |
Family
ID=46001313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101043A AR085724A1 (es) | 2011-03-29 | 2012-03-28 | ANALOGO DE LA SANGLIFERINA CON ACTIVIDAD INHIBIDORA DE mPTP |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9139613B2 (OSRAM) |
| EP (2) | EP2691412B1 (OSRAM) |
| JP (2) | JP6118793B2 (OSRAM) |
| KR (2) | KR101868084B1 (OSRAM) |
| CN (3) | CN103619869B (OSRAM) |
| AR (1) | AR085724A1 (OSRAM) |
| AU (2) | AU2012235880B2 (OSRAM) |
| BR (2) | BR112013024965A2 (OSRAM) |
| CA (2) | CA2830827C (OSRAM) |
| CL (2) | CL2013002739A1 (OSRAM) |
| CY (2) | CY1116318T1 (OSRAM) |
| DK (2) | DK2691412T3 (OSRAM) |
| EA (2) | EA023907B1 (OSRAM) |
| ES (2) | ES2533437T3 (OSRAM) |
| HR (2) | HRP20150184T1 (OSRAM) |
| IL (2) | IL228508B (OSRAM) |
| JO (1) | JO3063B1 (OSRAM) |
| MX (2) | MX345351B (OSRAM) |
| MY (2) | MY170618A (OSRAM) |
| PH (2) | PH12013502000B1 (OSRAM) |
| PL (2) | PL2691412T3 (OSRAM) |
| PT (2) | PT2691413E (OSRAM) |
| RS (2) | RS53963B1 (OSRAM) |
| SG (2) | SG193568A1 (OSRAM) |
| SI (2) | SI2691412T1 (OSRAM) |
| TW (1) | TWI525098B (OSRAM) |
| UY (1) | UY33993A (OSRAM) |
| WO (2) | WO2012131371A1 (OSRAM) |
| ZA (2) | ZA201307149B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9119853B2 (en) | 2010-02-09 | 2015-09-01 | Neurovive Pharmaceutical Ab | Sanglifehrin based compounds |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| CN103130734A (zh) * | 2011-12-01 | 2013-06-05 | 上海药明康德新药开发有限公司 | 一种合成1,2-吗啉盐酸盐的方法 |
| CN105695541B (zh) * | 2016-03-10 | 2019-03-15 | 苏州华赛生物工程技术有限公司 | 一种抗生素nvp018中间体的分离纯化方法 |
| KR20180036522A (ko) | 2016-09-30 | 2018-04-09 | (주)나노믹스 | 스틸벤 유도체 및 그 제조 방법 |
| AU2017361856A1 (en) | 2016-11-18 | 2019-05-23 | Neurovive Pharmaceutical Ab | Use of sanglifehrin macrocyclic analogues as anticancer compounds |
| CN112410353B (zh) * | 2019-08-23 | 2023-01-24 | 上海医药工业研究院 | 一种fkbS基因、含其的基因工程菌及其制备方法和用途 |
| CR20220241A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
| US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4334325A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN115028681B (zh) * | 2022-08-11 | 2022-11-15 | 中国科学院微生物研究所 | 一种降解亲环素a的嵌合体化合物及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| BRPI0613142A2 (pt) * | 2005-06-17 | 2010-12-21 | Novartis Ag | uso de sangliferina em hcv |
| CN105056207A (zh) | 2007-01-04 | 2015-11-18 | 德比奥法姆国际股份有限公司 | 用于治疗Ullrich先天性肌营养不良的非免疫抑制性环孢霉素 |
| CN101691575B (zh) * | 2008-09-24 | 2013-06-05 | 中国科学院上海有机化学研究所 | 一种萨菲菌素的生物合成基因簇 |
| JP5789190B2 (ja) | 2008-09-24 | 2015-10-07 | シャンハイ インスティテュート オブ オーガニック ケミストリー，チャイニーズ アカデミー オブ サイエンシズ | 新規の遺伝子クラスター |
| WO2011098808A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| WO2011098805A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| US9119853B2 (en) * | 2010-02-09 | 2015-09-01 | Neurovive Pharmaceutical Ab | Sanglifehrin based compounds |
| KR101935213B1 (ko) * | 2010-12-20 | 2019-01-03 | 뉴로바이브 파마슈티컬 에이비 | 상글리페린 유도체 및 이의 제조 방법 |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
-
2012
- 2012-03-12 JO JOP/2012/0053A patent/JO3063B1/ar active
- 2012-03-28 TW TW101110673A patent/TWI525098B/zh not_active IP Right Cessation
- 2012-03-28 AR ARP120101043A patent/AR085724A1/es unknown
- 2012-03-29 AU AU2012235880A patent/AU2012235880B2/en not_active Ceased
- 2012-03-29 PT PT127165397T patent/PT2691413E/pt unknown
- 2012-03-29 SG SG2013070966A patent/SG193568A1/en unknown
- 2012-03-29 KR KR1020137027773A patent/KR101868084B1/ko not_active Expired - Fee Related
- 2012-03-29 MX MX2013011043A patent/MX345351B/es active IP Right Grant
- 2012-03-29 DK DK12716538T patent/DK2691412T3/en active
- 2012-03-29 PL PL12716538T patent/PL2691412T3/pl unknown
- 2012-03-29 DK DK12716539T patent/DK2691413T3/en active
- 2012-03-29 MX MX2013011051A patent/MX345352B/es active IP Right Grant
- 2012-03-29 CN CN201280026190.3A patent/CN103619869B/zh not_active Expired - Fee Related
- 2012-03-29 ES ES12716538.9T patent/ES2533437T3/es active Active
- 2012-03-29 WO PCT/GB2012/050700 patent/WO2012131371A1/en not_active Ceased
- 2012-03-29 CA CA2830827A patent/CA2830827C/en not_active Expired - Fee Related
- 2012-03-29 PT PT127165389T patent/PT2691412E/pt unknown
- 2012-03-29 BR BR112013024965A patent/BR112013024965A2/pt not_active Application Discontinuation
- 2012-03-29 WO PCT/GB2012/050707 patent/WO2012131377A1/en not_active Ceased
- 2012-03-29 JP JP2014501720A patent/JP6118793B2/ja active Active
- 2012-03-29 SI SI201230145T patent/SI2691412T1/sl unknown
- 2012-03-29 CA CA2830831A patent/CA2830831C/en not_active Expired - Fee Related
- 2012-03-29 RS RS20150161A patent/RS53963B1/sr unknown
- 2012-03-29 BR BR112013024974A patent/BR112013024974A2/pt not_active Application Discontinuation
- 2012-03-29 EA EA201391396A patent/EA023907B1/ru not_active IP Right Cessation
- 2012-03-29 KR KR1020137028095A patent/KR101911484B1/ko not_active Expired - Fee Related
- 2012-03-29 HR HRP20150184TT patent/HRP20150184T1/hr unknown
- 2012-03-29 RS RS20150162A patent/RS53964B1/sr unknown
- 2012-03-29 SI SI201230146T patent/SI2691413T1/sl unknown
- 2012-03-29 EP EP12716538.9A patent/EP2691412B1/en active Active
- 2012-03-29 EA EA201391399A patent/EA023848B1/ru not_active IP Right Cessation
- 2012-03-29 MY MYPI2013701789A patent/MY170618A/en unknown
- 2012-03-29 AU AU2012235961A patent/AU2012235961B2/en not_active Ceased
- 2012-03-29 MY MYPI2013701788A patent/MY170637A/en unknown
- 2012-03-29 US US14/006,341 patent/US9139613B2/en active Active
- 2012-03-29 CN CN201611126823.4A patent/CN107417766A/zh active Pending
- 2012-03-29 PL PL12716539T patent/PL2691413T3/pl unknown
- 2012-03-29 JP JP2014501719A patent/JP6118792B2/ja not_active Expired - Fee Related
- 2012-03-29 CN CN201280026793.3A patent/CN103635484B/zh active Active
- 2012-03-29 PH PH1/2013/502000A patent/PH12013502000B1/en unknown
- 2012-03-29 PH PH1/2013/502016A patent/PH12013502016A1/en unknown
- 2012-03-29 UY UY0001033993A patent/UY33993A/es not_active Application Discontinuation
- 2012-03-29 SG SG2013070974A patent/SG193569A1/en unknown
- 2012-03-29 EP EP12716539.7A patent/EP2691413B1/en active Active
- 2012-03-29 HR HRP20150187TT patent/HRP20150187T1/hr unknown
- 2012-03-29 US US13/433,944 patent/US9090657B2/en active Active
- 2012-03-29 ES ES12716539.7T patent/ES2533438T3/es active Active
-
2013
- 2013-09-17 IL IL228508A patent/IL228508B/en active IP Right Grant
- 2013-09-17 IL IL228509A patent/IL228509B/en active IP Right Grant
- 2013-09-23 ZA ZA2013/07149A patent/ZA201307149B/en unknown
- 2013-09-25 CL CL2013002739A patent/CL2013002739A1/es unknown
- 2013-09-25 CL CL2013002740A patent/CL2013002740A1/es unknown
- 2013-09-26 ZA ZA2013/07231A patent/ZA201307231B/en unknown
-
2015
- 2015-02-27 CY CY20151100207T patent/CY1116318T1/el unknown
- 2015-03-06 CY CY20151100236T patent/CY1116186T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085724A1 (es) | ANALOGO DE LA SANGLIFERINA CON ACTIVIDAD INHIBIDORA DE mPTP | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| DOP2012000243A (es) | Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales | |
| NI201500128A (es) | 3- pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| CU24335B1 (es) | Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer | |
| PA8740901A1 (es) | Compuestos organicos | |
| DOP2016000017A (es) | Nuevos compuestos tricíclicos | |
| GT201500348A (es) | Compuestos de pirimidinodiona contra estados cardíacos | |
| CR20150183A (es) | Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih | |
| ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
| MX2015006039A (es) | Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer. | |
| CR20130023A (es) | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral | |
| PE20150887A1 (es) | Compuestos de benceno sustituidos | |
| UY31679A1 (es) | Inhibidores de cinasa pim y metodos para su uso | |
| GT201400131A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| MX2022001697A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| UY33885A (es) | Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes | |
| UY31803A (es) | Compuesto cristalino | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| CO6440593A2 (es) | Procedimientos para mejorar la farmocinética | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| CO6781541A2 (es) | Derivados glucósidos y usos de los mismos | |
| BR112014008555A2 (pt) | r(+)-n-formil-propargil-aminoindano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |